Home / Stocks / Anthem Biosciences Ltd
ANTHEM

Anthem Biosciences Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹936.8

Change

+22.45 (2.46%)

Open

₹910.0

Prev. Close

₹914.35

Day High

₹939.05

Day Low

₹910.0

Volume Analysis

Traded

450,325

Delivered

209,218

Delivery %

46.46%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (22.3%)
  • •Strong operating margin (41.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (3)

  • •Strong 3-year EPS growth (15.4%)
  • •Strong 3-year revenue growth (26.2%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹976.29 ₹957.67 ₹947.24 ₹928.62 ₹918.19 ₹899.57 ₹889.14
Fibonacci ₹957.67 ₹946.57 ₹939.72 ₹928.62 ₹917.52 ₹910.67 ₹899.57
Camarilla ₹944.79 ₹942.13 ₹939.46 ₹928.62 ₹934.14 ₹931.47 ₹928.81

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+46.81%

1 Week

-0.18%

1 Month

+16.29%

3 Months

+7.5%

6 Months

+20.55%

1 Year

+44.69%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹42.36

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

56.66%

Net margin 30.01% × asset turnover 0.87x × equity multiplier 2.17x

Company Overview

Sector

Healthcare

Market Cap

₹51,355 Cr

P/E (TTM)

81.4

ROE

22.3%

Book Value

₹58.2

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Anthem Biosciences Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 75/100. The strongest factor is Financial Strength (100/100), while Valuation (1/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (22.3%); strong operating margin (41.0%); promoter holding is falling. Strong 3-year EPS growth (15.4%).

TopFund Score — Fundamentals Quality

75/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

82

Valuation

1

Cash Flow

75

Corporate Governance

75

Momentum

81

Institutional Ownership

62

Business Quality

97

Risk & Volatility

86

Liquidity

76

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company's working capital requirements have reduced from 118 days to 92.3 days
  • −Stock is trading at 15.7 times its book value

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of Q2 & H1 FY27 Earnings Conference Call

Audio recording of Q2/H1 FY2026 earnings call made available on company website.

Newspaper publication on Unaudited Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2026

Investors presentation for the financial results for the quarter and half year ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 339 525 498 483 540 550 423 611 418 594
Expenses + 218 330 338 288 349 332 266 344 268 323
Operating Profit 121 195 160 195 191 218 157 267 151 271
OPM % 36.0% 37.0% 32.0% 40.0% 35.0% 40.0% 37.0% 44.0% 36.0% 46.0%
Other Income + 19 28 24 14 23 48 8 52 25 59
Interest 4 4 3 1 2 3 0 2 1 3
Depreciation 19 20 20 30 26 34 35 40 30 31
Profit before tax 118 200 161 178 186 230 130 278 145 296
Tax % 30.0% 19.0% 23.0% 54.0% 27.0% 24.0% 29.0% 32.0% 17.0% 29.0%
Net Profit + 82 162 124 83 136 173 93 190 120 211
EPS in Rs 1 3 2 1 2 3 2 3 2 4
Raw PDF — — — — — — — — — —
YoY Sales growth — — — — 60 5 -15 26 -23 8

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 626 633 1,103 1,231 1,057 1,419 1,845 2,124 2,046
Expenses + 454 451 695 666 626 914 1,173 1,290 1,200
Operating Profit 172 182 408 565 431 506 672 834 846
OPM % 27.0% 29.0% 37.0% 46.0% 41.0% 36.0% 36.0% 39.0% 41.0%
Other Income + 21 21 37 49 139 63 85 131 144
Interest 18 20 17 10 9 10 11 7 6
Depreciation 61 62 62 58 64 82 89 134 135
Profit before tax 114 121 366 546 497 477 657 824 849
Tax % 32.0% 23.0% 26.0% 26.0% 23.0% 23.0% 31.0% 28.0% —
Net Profit + 77 93 271 406 385 367 451 592 614
EPS in Rs 1 2 5 7 7 7 8 11 11
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 19.0% —
Sales growth — — 74 12 -14 34 30 15 -1

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 323 413 693 1,346 1,627 1,813 2,298 2,930 3,168
Borrowings + 192 159 100 35 126 239 113 54 40
Other Liabilities + 194 207 232 228 148 235 284 333 365
Total Liabilities 718 787 1,034 1,619 2,014 2,398 2,808 3,429 3,686
Fixed Assets + 316 306 361 329 449 483 705 783 768
CWIP 12 50 19 154 164 345 297 264 309
Investments 73 99 209 273 499 472 433 1,007 1,261
Other Assets + 318 333 445 863 902 1,099 1,373 1,374 1,348
Total Assets 718 787 1,034 1,619 2,014 2,398 2,808 3,429 3,686
Equity Capital 8 8 8 9 114 112 112 112 113

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 196 166 278 333 306 140 271 844
Cash from Investing Activity + -121 -109 -196 -205 -376 -221 -147 -702
Cash from Financing Activity + -65 -48 -63 181 64 -77 -136 -40
Net Cash Flow 9 9 18 308 -6 -158 -12 103
Free Cash Flow 144 119 159 307 112 -156 12 637
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 114 116 85 81 98 51 64 126

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 74.69% → 71.39%
  Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 16.42% 16.34% 12.48% 12.52% 12.71%
Promoters 74.69% 74.69% 74.67% 71.42% 71.39%
FII 1.66% 1.37% 1.28% 2.57% 3.79%
DII 7.21% 7.6% 11.55% 13.48% 12.1%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Anthem Biosciences Ltd (this stock) 51,355 81.4 15.65 22.3%
Gland Pharma Limited 53,710 42.9 5.01 10.7%
Ipca Laboratories Ltd 46,508 32.3 5.36 15.7%
Glaxosmithkline Pharma Lt 45,576 40.2 24.22 45.6%
Emcure Pharmaceuticals L 44,370 39.9 8.29 20.1%
Biocon Limited. 58,962 86.5 1.69 1.4%
Fortis Healthcare Ltd 61,047 56.9 5.81 11.2%

Which Mutual Funds Hold Anthem Biosciences Ltd?

Frequently Asked Questions about Anthem Biosciences Ltd

Community Sentiment

What are other investors saying about Anthem Biosciences Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.